Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Beximco Delivers First Cut-Price Generic Paxlovid

Executive Summary

Bangladesh’s Beximco signed off 2021 on a high launching the first generic version of Pfizer’s Paxlovid at about $186 for a five-day treatment course and claimed that it has ‘adequate capacities' for exports as well.

You may also be interested in...



The Generics Bulletin Top 50, Part Three: Newcomers Climb Into Bottom Table

In the third section of this year’s Generics Bulletin Top 50, a handful of new entrants make their way into the bottom of the rankings, while some volatility is seen among longstanding ranking companies.

MPP Announces Generic Paxlovid Licences For LMICs

A group of 35 generics manufacturers have signed agreements with the Medicines Patent Pool to supply Paxlovid generics to 95 low- and middle-income countries.

Calls For COVID Patent Waivers Persist As Pooling Initiatives Plough Ahead

The formulas for various COVID-19 vaccines remain shrouded in intellectual property protections – one of many factors preventing them from being manufactured in developing nations. Those in favor of upholding IP say that scrapping patents could stifle future innovation, but their opponents believe preserving COVID-19 related IP rights is limiting access to lifesaving medical tools.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151524

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel